الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 96 |  |  |
| | | from | 96 | | |
Abstract
Primary monosymptomatic nocturnal enuresis (PMNE) is enuresis in children who are at least 5 years old without any other lower urinary tract symptoms and without a history of bladder dysfunction; children who have never achieved a satisfactory period of nighttime dryness.
Solifenacin succinate is a competitive muscarinic antagonist, with selectivity for the M3 receptor in the urinary bladder. The binding of solifenacin to M3 receptors led to a decrease in intracellular calcium levels, resulting in a reduction in bladder intravesical pressure and subsequent smooth muscle contractility.
Within the last few years, many studies were published concerning the use of solifenacin in children, however, limited number of them have investigated its efficacy as a single treatment for PMNE. The aim of this study is to assess the safety and efficacy of solifenacin in treatment of PMNE in combination to behavioral therapy given to both study groups.
The study included 86 patients attending the urology clinic in Suez Canal University Hospital, Ismailia General Hospital and Suez Canal Authority Hospital in Ismailia Governorate. Patients who were diagnosed as having PMNE by history taking and clinical criteria according to ICCS were randomized into 2 equal groups.
Better response recorded as fewer bed wet nights for the solifenacin group had statistically significant difference (p> 0.002) compared to the behavioral therapy group. Minimal side effect for the solifenacin group as a total 8 out of 43 (18.6 %) patients reported adverse side effects of the drug.
No serious adverse effects were reported in the solifenacin group, mainly constipation (3 out of 8 patients) with no effect on the continuation the treatment.